



WRESP-RC
Warfighter Refractive Eye Surgery Program & Research Center at Fort Belvoir



Optical Quality and Levels of Tear Protein Lacritin after Photorefractive Keratectomy

Denise S. Ryan¹, Rose K. Sia¹, Alan C. Tate², Robert L. McKown², Richard D. Stutzman³, Kraig S. Bower⁴

¹Warfighter Refractive Eye Surgery Program and Research Center at Fort Belvoir, Fort Belvoir, VA, USA

²James Madison University, Harrisonburg, VA, USA

³Ophthalmology, Walter Reed National Military Medical Center, Bethesda, MD, USA

⁴The Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA

The authors have no financial interest in the subject matter of this poster.


This work is supported by U.S. Army Medical Research and Materiel Command

Grant # W81XWH-11-1-0838

Background

Lacritin is a naturally occurring tear protein capable of:

- Stimulating mitogenesis in human corneal epithelial cells (HCE)¹
- Promoting production of tears²⁻⁴
- Protecting cells against interferon gamma / tumor necrosis factor- dependent cell death⁵
- Protecting cells against benzalkonium chloride induced damage⁶



²Lacritin Size
12.3 kDa


Background

- Because of its ability to stimulate regeneration of HCE, lacritin may promote re-epithelialization following PRK.
- Native lacritin and its constructs have been shown to have a significant antimicrobial effect in vitro.⁷

Lacritin's properties make it an intriguing and potentially potent therapeutic adjunct in the modulation of post-refractive surgery wound healing.

Purpose

The purpose of this study was to determine whether the level of tear protein lacritin affects optical quality following photorefractive keratectomy (PRK).



Methods

Prospective study of 52 myopic patients undergoing PRK:

- PRK Procedure:
 - Epithelial debridement using Amoils brush
 - Photoablation using the Allegretto Wavelight Eye Q Excimer Laser System
 - Prophylactic mitomycin C (MMC) used when ablation depth greater than 75 microns.
 - Bandage contact lens applied (Omafilicon-A, Proclear®)
- Topical Postoperative regimen:
 - Moxifloxacin 0.5% 4x daily for 1 week or until complete re-epithelialization
 - Fluorometholone 0.1% 4x daily for 4 weeks followed by a 6-week taper
 - Preservative-free ketorolac 0.5% up to 4x daily for 48 hours
 - Preservative-free carboxymethylcellulose 0.5% 1 drop every hour for the first week, then at least every 2 hours or more for several months
- Tear samples from the left eye were collected preoperatively and postoperatively on day 1, week 1, months 1, 3 and 6:
 - One drop of proparacaine 0.5%
 - After 2 minutes, tears were collected from lower conjunctival cul-de-sac using polyester fiber wick (Filtrona, Richmond, VA)

Methods

- Optical quality was assessed using the following indices (Tomey TMS-4, Tomey Inc, NY):
 - Surface Regularity Index (SRI)
 - * Measures local fluctuations in central corneal power and its impact on optical quality. Elevated SRI is indicative of corneal surface irregularity. High SRI has been noted in dry eye.⁸
 - Surface Asymmetry Index (SAI)
 - * Measures the difference in corneal power over the entire corneal surface. Eyes with elevated SAI cannot achieve optimal spectacle correction.
 - Irregular Astigmatism Index (IAI)
 - * Measures average power variation along every meridian of the corneal surface. IAI increases as irregularity increases.
- James Madison University completed tear sample analysis for lacritin levels using enzyme-linked immunosorbent assay (ELISA). Each tear sample was analyzed in triplicate with its own standard curve and repeated on a second microtiter plate.
- Data analysis
 - Repeated measures analysis of variance was used to compare baseline optical quality and lacritin to post-surgical levels. Test results from left eye were used for data analysis.
 - Multivariate analysis of variance was performed to determine if lacritin had any significant correlation with optical quality.


Results

The mean age was 30.5 ± 6.7 years with 34.6% of the participants being female.

MMC was used in 17.3% of cases. The average percentage of lacritin preoperatively was 12.1 ± 2.6 (expressed as nanograms [ng] lacritin/ 100 ng total protein).

Preoperative clinical data (n=52)	
Manifest Sphere (diopters)	-2.59 ± 1.72
Manifest Cylinder (diopters)	-0.55 ± 0.55
Manifest Spherical Equivalent (diopters)	-2.86 ± 1.70
Ablation depth (microns)	46.17 ± 21.6
Best Corrected Visual Acuity (logMAR)	-0.11 ± 0.03

Results




Optical quality results over time:

- Postoperative SRI did not change significantly over time ($p=0.76$).
- SAI changed significantly over time ($p<0.01$) most notably at 1 month post-op ($P=0.01$).
- IAI changed significantly over time ($P<0.01$) most notably at 1 month post-op ($P<0.01$).

Results


% Average Tear Lacritin Levels



- Lacritin concentration over time: Lacritin levels changed significantly over time ($p < 0.01$) with a notable decrease from pre-op levels one day postoperatively ($P = 0.03$).
- Lacritin did not correlate with TMS indices at pre-op ($P = 0.20$), at 1M ($P = 0.70$), or at 3M postop ($P = 0.78$).

Results

- In participants with abnormal optical indices (noted as > 0.50) six months post-operatively, there was no significant difference in percentage of average lacritin between the participants with normal SRI, SAI, and IAI 6 months post-PRK compared to the participants with abnormal SRI ($P=0.53$), SAI ($P=0.19$), and IAI ($P=0.73$).



Conclusions

- Average percentage of lacritin decreased significantly in the early post-operative period. The cause and significance of this finding is still being explored.
- Initial results showed lacritin levels did not correlate with optical quality, as measured by surface regularity, surface asymmetry and irregular astigmatism indices.
- The average percentage of lacritin in the early postoperative period does not appear to affect optical quality in those participants with chronic abnormal optical indices in the late postoperative period.
- The association between LASIK and lacritin is still being investigated as part of an ongoing study.

References

1. Wang J, et al. Restricted epithelial proliferation by lacritin via PKC alpha-dependent NFAT and mTOR pathways. *J Cell Biol* 2006;174(5):689
2. Sanghi S, et al. cDNA and genomic cloning of lacritin, a novel secretion enhancing factor from the human lacrimal gland. *J Mol Biol* 2001;310(1):127
3. Spitze AR, et al. Extended treatment with lacritin, a novel tear glycoprotein, stimulates tear production in rabbits ARVO, Program/Poster #5581/B351, April-May 2006
4. Lossen V, et al. Lacritin, a novel tear glycoprotein, is more efficacious and better tolerated than cyclosporin. ARVO, Program/Poster #4662/D906, May 2009
5. Wang N, et al. Human corneal epithelial INFG/TNF-dependent cell death (ITDCD) and protection by tear prosecretory mitogen lacritin. ARVO, Program/Poster #4265/D868, May 2009
Nichols JJ, Green-Church KB. Mass spectrometry-based proteomic analyses in contact lens-related dry eye. *Cornea*. 2009; 28: 1109–1117.
6. Baryla J, et al. The effect of lacritin on HCE cells exposed to BAK or tert-butyl hydroperoxide. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Program/Poster #4617/D820, May 2009
7. McKown RL, et al. Lacritin and other new proteins of the lacrimal functional unit. *Exp Eye Res* 2009;88(5):848
8. Courville CB, Klyce SD, Corneal Topography. In: Forster CS, Azar DT, Dohlman, Smolin and Thoft's *The cornea: scientific foundations and clinical practice*. 4th ed. Philadelphia PA: Lippincott Williams & Wilkins; 2005: 175-186.